Colorectal cancer (CRC) is the third most diagnosed cancer and has the second biggest mortality, accounting for 10% of cancer-related deaths worldwide. BRAF gene is a proto-oncogene from the RAF family. It is an important part of RAS/RAF/MEK/ERK pathway, or MAPK (mitogenactivated protein kinase) pathway, inducing cell proliferation, growth and apoptosis. For many years the presence of BRAF mutations in CRC has been associated with a poor prognosis. But since the successful emergence of anti-BRAF inhibitors for melanoma, this therapy could be promising. However, anti-BRAF monotherapy to BRAF V600E-mutated CRC is not effective due to EGFR feedback activation. Hence, anti-BRAF inhibitors in combination with EGFR or MEK inhibitors, can be a promising therapy in advanced CRC, as we will discuss in this review.